<DOC>
	<DOCNO>NCT02389244</DOCNO>
	<brief_summary>INDICATION : Metastatic bone sarcoma : conventional high grade osteosarcoma , Ewing sarcoma bone , intermediate high-grade chondrosarcoma chordomas</brief_summary>
	<brief_title>A Phase II Study Evaluating Efficacy Safety Regorafenib Patients With Metastatic Bone Sarcomas</brief_title>
	<detailed_description>METHODOLOGY : Randomized , placebo-controlled , multicentric , phase II study -This double-blind placebo-controlled trial , 4 cohort : cohort A : Osteosarcoma cohort B : Ewing sarcoma cohort C : Chondrosarcoma cohort D : chondroma . Cohort A , B C involve total 36 patient ( 24 Regorafenib + 12 placebo ) . And cohort D total 24 evaluable patient ( 16 Regorafenib + 8 placebo ) 132 patient meet eligibility criterion randomly assign 2:1 ratio follow treatment group : The Arm A : Regorafenib ( 160 mg/d ) daily 3 week / 1 week plus Best Supportive Care ( BSC ) progression ( accord RECIST 1.1 ) , intolerance withdrawal consent . Patients receive regorafenib experience disease progression investigator opinion , treatment regorafenib provide clinical benefit , may continue treatment follow consultation study coordinator sponsor . The Arm B : Placebo plus BSC progression ( accord RECIST V1.1 ) intolerance withdrawal consent . Patients receive placebo receive open-label regorafenib objective tumor progression . Patients stratify randomization accord histology .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Chondroma</mesh_term>
	<criteria>1 . Patients must histologically confirm diagnosis bone sarcoma ( osteosarcoma , Ewing sarcoma bone , chondrosarcoma chordoma ) ; 2 . Patients confirm disease progression study entry . 3 . Metastatic disease amenable surgical resection radiation curative intent ; 4 . Patients must measurable disease ; 5 . Prior treatment : least one , two prior chemotherapy regimen metastatic disease osteosarcoma , chondrosarcoma Ewing sarcoma ; neoadjuvant /maintenance therapy count towards requirement . Chordoma pretreated 1 2 prior ( combination ) chemotherapy regimen one two prior molecularly target therapy , 2 prior line treatment ( whatever indication ) include . At least 4 week since last chemotherapy ( 6 week case nitrosoureas mitomycin C ) , immunotherapy pharmacological treatment and/or radiotherapy ; 6 . Age ≥ 18 year ; 7 . Life expectancy great 3 month ; 8 . ECOG ( Developed Eastern Cooperative Oncology Group ) performance status &lt; 2 ( Karnofsky ≥ 60 % ) ; 9 . Patients must adequate bone marrow , renal , hepatic function , evidence follow within 7 day study treatment initiation : normal organ function define : Absolute neutrophil count ≥ 1.5 Giga/L Platelets ≥ 100 Giga/L Hemoglobin≥ 9 g/dL Serum creatinin ≤ 1.5 x ULN ( Upper Limit Normal ) Glomerular filtration rate ( GFR ) ≥30 ml/min/1.73m2 accord modify Diet Renal Disease ( MDRD ) abbreviate formula AST ( aspartate transaminase ) ALT ( alanine transaminase ) ≤2.5 x ULN Bilirubin ≤1.5 X ULN Alkaline phosphatase ≤2.5 x ULN ( ≤5 x ULN patient liver involvement cancer ) . If Alkaline phosphatase &gt; 2.5 ULN , hepatic isoenzymes 5nucleotidase GGT test must perform ; hepatic isoenzymes 5nucleotidase must within normal range and/or GGT &lt; 1.5 x ULN lipase ≤1.5 x ULN . Spot urine must show 1+ protein urine patient require repeat urine analysis . If repeat urinalysis show 1+ protein , 24hour urine collection require must show total protein excretion &lt; 1000 mg/24 hour 10. International Normalized Ratio ( INR ) / Partial Thromboplastin Time ( PTT ) ≤1.5 x ULN ; 1 . Prior treatment VEGFR inhibitor ; 2 . Soft tissue sarcoma ; 3 . Other cancer ( different histology ) within 5 year prior randomization ; 4 . Major surgical procedure , open biopsy , significant trauma , within last 28 day randomization ; 5 . Cardiovascular dysfunction : Left ventricular ejection fraction ( LVEF ) &lt; 50 % Congestive heart failure ( New York Heart Association [ NYHA ] ) ≥ 2 Myocardial infarction &lt; 6 month study Cardiac arrhythmia require therapy Uncontrolled hypertension Unstable angina newonset angina 6 . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , pulmonary embolism within last 6 month randomization ; 7 . Severe hepatic impairment ( ChildPugh C ) ; 8 . Ongoing infection &gt; Grade 2 accord NCICTCAE v4.0 ; 9 . Known history human immunodeficiency virus ( HIV ) infection ; 10 . Active hepatitis B C chronic hepatitis B C require treatment antiviral therapy ; 11 . Difficulties swallow study tablet ; 12 . Interstitial lung disease ongoing sign symptoms time informed consent ; 13 . Nonhealing wound , nonhealing ulcer , nonhealing bone fracture ; 14 . Patients evidence history bleed diathesis , irrespective severity ; 15 . Any hemorrhage bleeding event ≥ CTCAE Grade 3 within 4 week prior start study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>